Fortitude Biomedicines in Nature Cancer Journal

Is Tethis' SmartBioSurface® the next big leap in advanced diagnostics? Today, Tethis S.p.A. commercially launched its SmartBioSurface® slides at the EACR Conference, introducing a proprietary nanostructured titanium coating poised to revolutionize rare and suspension cell analysis. This innovation addresses critical unmet needs, ensuring high cell adhesion and preserved morphology for challenging samples like circulating tumor cells. By overcoming limitations of conventional methods, SmartBioSurface® sets Tethis as a key innovator positioned to capitalize on the expanding liquid biopsy and advanced diagnostics market. Learn more about this game-changing technology: https://lnkd.in/gApcUR7Q #Tethis #SmartBioSurface #LiquidBiopsy #Diagnostics #LifeSciences

We’re pleased to share our latest white paper exploring advancements in rapid, cost-effective GoFast™ CAR-T manufacturing on MARS. This paper presents validation data for the GoFast™ CAR-T workflow on the MARS Atlas® platform, highlighting performance across multiple starting materials, in vitro function comparisons, repeated antigen stimulation studies, and in vivo mouse model evaluations.   For teams advancing #CART process development and translational strategies, this white paper offers valuable insights into simple and working approaches designed to improve operational efficiency without compromising therapeutic potential. Download here: https://lnkd.in/gNWZsQpd #CellTherapy #Immunotherapy #RapidCellTherapy

📣Call for Reading: #Review Expanding Horizons in Advancements of FRET Biosensing Technologies By Munazza Fatima, Naseem Abbas https://lnkd.in/gP7d7u_j Abstract: Förster resonance energy transfer (FRET)-based biosensors are versatile tools for obtaining insights into various biological processes. Their working principles are based on nonradiative energy transfer from donor to acceptor fluorophores. This energy transfer is responsible for a change in fluorescence intensity, which provides a basis for the detection of biomolecules. Advantageous features of FRET biosensors include their high sensitivity and specificity. Recently, there have been notable developments to extend the usage of FRET biosensors for diverse applications. In this review, we briefly summarize the state-of-the-art developments of FRET biosensors for cellular imaging, drug discovery, pathogen detection, and cancer diagnosis. Continued research on biosensor design, donor acceptor pair optimization, and integration of innovative materials can further extend the applications of FRET biosensors across health care settings. #FRET #imaging #pathogen #diagnosis #biosensor #open_access

A new non-invasive methodology to estimate the biopersistence of novel antibodies for intravitreal therapies 👁️ 💉 in this case, a bispecific antibody targeting VEGF-A and ANG-2 (Faricimab) for Age-related Macular Degeneration Our methodology enables quantitative PET imaging of ocular biopersistence, intravitreal release pharmacokinetics, and whole-body systemic distribution and clearance. We are completely ready for 🚀 ◾ Compare intraocular retention between disease versus healthy conditions (e.g. Age-related Macular Degeneration) ◾ Validate your intravitreal drug-delivery systems aimed at increasing intraocular retention (e.g. nanoparticles, implants, gels...) Once again, a fantastic collaboration with Anxo Fernández Ferreiro very well driven by Xurxo García Otero and Andrea Cuartero Martinez Link: https://lnkd.in/e3ckgxpc CiMUS (Center for Research in Molecular Medicine and Chronic Diseases) Instituto de Investigación Sanitaria de Santiago de Compostela

From sample preparation to research and treatment, automation continues to play an increasingly important role in advancing cancer research and precision medicine. The Lynx Liquid Handler supports a wide range of oncology-focused workflows designed to improve throughput, reduce sample waste, and deliver reliable, reproducible results for researchers and clinicians alike. Applications include: 🧬 Sample Prep: Automated DNA extraction using Omega Bio-tek purification kits or resin-filled IMCStips 🔬 Screening & Diagnosis: Rare allele detection through RhoDx’s PointSuppressor technology 👩🔬 Research & Treatment: VVP-powered high-throughput combo dosing and DOE workflows for treatment response analysis Whether supporting early mutation detection, purification workflows, or translational oncology research, flexible liquid handling helps labs move faster while maintaining confidence in their results. #CancerResearch #LabAutomation #LiquidHandling #LifeSciences #PrecisionMedicine

Happy Wednesday all! Check out this open access Cell paper by Bjelejac et al., "Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis." We sought to endow T cell autonomous regulation of cell surface protein expression by exploiting the conditional proteolytic activity of ADAM17 following T cell activation. Screening of canonical ADAM17 substrates yielded a minimal 15-aa CD62L-derived motif that confers rapid and reversible cleavage of a receptor following T cell activation—termed activation-induced release (AIR). Embedding AIR into tonic-signaling CARs reduced basal CAR expression proportional to the degree of tonic signaling induced, curtailing exhaustion and improving antitumor potency. In non-tonic signaling CARs, AIR decreased activation-induced cell death and enhanced T cell expansion after stimulation. AIR’s modularity supports higher-order logic-gating; AIR-regulated peptide masks enable antigen-dependent unmasking of an EGFR-targeting CAR. Finally, CRISPR knockin of AIR into endogenous FAS or TGFBR2 endowed them with activation-induced shedding, which enhanced tumor clearance while preserving signaling in non-activating conditions. AIR is a compact switch that provides fast, autonomous regulation of surface proteins for next-generation cell therapies. https://lnkd.in/gC2uvfnz #drugdiscovery #drugdevelopment #cancerresearch #tumors #immunotherapy #cartcelltherapy #adam17 #immunooncology #nextgentherapeutics #scientificresearch

Cells can sometimes accept mitochondria from outside. The hard part is delivery. A new Cell paper tested mitochondria packed into protective capsules. The capsule helps the organelle reach damaged cells instead of getting degraded on the way in. In mitochondrial disease and Parkinson's models, that improved energy function. Still preclinical, but the framing is interesting: organelle therapy, not another small molecule. Source: https://lnkd.in/eaKMJA3x

𝗣𝗼𝘀𝘁𝗲𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝘁 𝗠𝗣𝗦 𝗪𝗼𝗿𝗹𝗱 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟲. 𝗣𝗼𝘀𝘁𝗲𝗿 #𝟯𝟰𝟮 | 𝗔𝗯𝘀𝘁𝗿𝗮𝗰𝘁 #𝟳𝟲𝟳 📅 𝗧𝗼𝗱𝗮𝘆, 𝗠𝗮𝘆 𝟮𝟴 | 𝟭𝟬:𝟬𝟬–𝟭𝟭:𝟯𝟬 𝗔𝗠 | Walter E. Washington Convention Center John Huang, Ph.D. will present a poster by Rick I. Cohen, Ph.D. in collaboration with Hamamatsu Corporation: Volumetric time-course analysis of chemotherapeutic dose-response in 3D hydrogel embedded cancer spheroids using VitroPrime™ 3D Culture and Imaging Plates together with CYTOQUBE light-sheet microplate cytometer. This work tracks oxidative stress, apoptosis, and necrosis in U87 3D cultures over 96 hours using an integrated workflow combining 𝗩𝗶𝘁𝗿𝗼𝗚𝗲𝗹® 𝗚𝗕𝗠 𝗫𝗲𝗻𝗼-𝗙𝗿𝗲𝗲 𝗘𝗠𝗧 𝗞𝗶𝘁, 𝗩𝗶𝘁𝗿𝗼𝗣𝗿𝗶𝗺𝗲™ 𝟯𝗗 𝗖𝘂𝗹𝘁𝘂𝗿𝗲 𝗮𝗻𝗱 𝗜𝗺𝗮𝗴𝗶𝗻𝗴 𝗣𝗹𝗮𝘁𝗲𝘀, and Hamamatsu's 𝗖𝗬𝗧𝗢𝗤𝗨𝗕𝗘 light-sheet technology, with dose-dependent cell death confirmed at TMZ concentrations known to be toxic to GBM cells. 📄 Access the poster: https://lnkd.in/dJKrCMBx 🔬 Visit us at Booth #226 to explore our full end-to-end xeno-free platform. #MPSWorldSummit #3DCellCulture #DrugDiscovery #Organoids #NAMs #TheWellBioscience #Biotech #LifeSciences

Before a drug candidate moves forward, researchers need to answer 4 critical questions.    From tracking tumor-specific uptake to monitoring early therapy response and evaluating safety profiles, molecular imaging provides researchers with answers in the drug development process.    In this carousel, we highlight 4 application examples showing how preclinical PET, SPECT, and CT imaging can help ⬇️ 

🌍 FluoSphera is excited to attend the Microphysiological Systems World Summit in Washington, DC, from May 26–29! 🚀 At FluoSphera, we facilitate the integration of 3D cell culture into drug discovery workflows with ready-to-use encapsulated spheroids and organoids. 🔬 With the same technology, our platform can scale from single 3D models to multi-tissue systems, enabling more human-relevant insights into systemic effects and tissue–tissue interactions, with the mission of discovering better drugs for patients. 👩 Clélia Bourgoint will represent FluoSphera at the summit and will present poster #301 during the Thursday, May 28 afternoon session. 🤝 Attending the summit? Clelia would be happy to connect and discuss how FluoSphera can support your next-generation in vitro studies. #MPSWorldSummit #MicrophysiologicalSystems #3DCellCulture #Organoids #Spheroids #NAMs #DrugDiscovery